Singapore markets closed

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
28.33+0.24 (+0.85%)
At close: 05:35PM CET

Bayer Aktiengesellschaft

Kaiser-Wilhelm-Allee 1
Leverkusen 51368
Germany
49 214 30 1
https://www.bayer.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees100,873

Key executives

NameTitlePayExercisedYear born
Mr. Wolfgang U. NicklCFO & Member of Management Board2.12MN/A1969
Mr. Heiko W. J. SchipperMember of Management Board & President of the Consumer Health Division1.92MN/A1969
Mr. Stefan OelrichHead of the Pharmaceuticals Division & Member of the Board of Management2.08MN/A1968
Mr. Rodrigo SantosMember of Management Board & President of the Crop Science Division2.17MN/A1973
Mr. William N. AndersonChairman of the Management Board & CEON/AN/A1966
Ms. Heike PrinzChief Talent Officer, Labor Director & Member of Management BoardN/AN/A1965
Dr. Jost ReinhardHead of Investor RelationsN/AN/A1972
Mr. Michael PreussHead of Communications, Government Relations and Corporate BrandN/AN/AN/A
Mr. Bernd-Peter BierHead of Group FinanceN/AN/A1967
Mr. Robert LaCazeExecutive VP & Head of the Oncology Strategic Business UnitN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases, as well as collaboration with Bicycle Therapeutics to develop bicyclic peptides. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Corporate governance

Bayer Aktiengesellschaft’s ISS governance QualityScore as of 1 March 2024 is 6. The pillar scores are Audit: 10; Board: 2; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.